Interestingly, our previous data indicated that sorafenib, an analog of regorafenib, shows significant anti-EMT activity in vitro and in vivo in a HCC preclinical model via directly activating PTPase SHP-1-dependent p-STAT3Tyr705 suppression [14]. This evidence concerns the gene PTPN6 and hepatocellular carcinoma.